Quotient Therapeutics Raises $50M in Initial Funding

Quotient Therapeutics, a Cambridge, MA- and Cambridge, UK-based company advancing somatic genomics, raised $50 million in initial funding led by Flagship Pioneering. The company intends to use the funds to advance development of its platform, which studies natural selection at the cellular level to discover transformative therapies.

Quotient Therapeutics Secures $50 Million in Initial Funding

Quotient Therapeutics is a Cambridge, MA- and Cambridge, UK-based company advancing somatic genomics. The company works to systematically study the genetic variation and evolution of the trillions of cells inside the human body. Its Somatic Genomics platform reveals links between genes and disease across a broad range of therapeutic areas, enabling the discovery of transformative medicines intended to cure, prevent, or reverse disease. Created by Flagship scientists in partnership with geneticists at the Wellcome Sanger Institute and the University of Texas Southwestern, this platform is able to study natural selection at the cellular level through four steps: phenotyping of cells from clinical tissue samples, isolation, single cell genotyping, and computation. As a result, naturally selected genes, proteins, and pathways are identified as prospective targets for the development of transformative therapies intended to cure, prevent, or reverse disease. Quotient’s approach will enable the development of first-in-class drugs across a broad range of modalities and therapeutic areas, including immune disease, cardiometabolic disease, infectious disease, oncology, neurodegenerative disease, rare disease, and aging.

Quotient Therapeutics is a company advancing somatic genomics, working to systematically study the genetic variation and evolution of the trillions of cells inside the human body.

a year ago

Quotient Therapeutics Secures $50 Million in Initial Funding

ProblemTechnology

Solution

Covered on